Winning New API and Intermediate Projects through Pharmaceutical Facility Investment
First written in FY2016. 8 of 13 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2020.
Yuki Gosei Kogyo moved to the "Worse" side of this theme in 2020.
The whole theme swung hardest in 2020: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2020ReframedAnnual report
「④ Utilization of new pharmaceutical facilities and expansion of the new product development framework We will expand sales by utilizing the new pharmaceutical facilities to strengthen our new product development framework.」
The focus shifted from the construction investment phase for the completed facilities to utilizing the facilities and expanding the new product development framework under the medium-term plan for fiscal 2020 through fiscal 2022. - FY2019RestatedAnnual report
「In addition, there is approximately ¥3.6 billion of new pharmaceutical facilities at the Tokiwa Plant that was recorded as construction in progress in the previous fiscal year and transferred to the property, plant and equipment account in the current fiscal year.」
Approximately ¥3.6 billion of new pharmaceutical facilities at the Tokiwa Plant was transferred from construction in progress to the property, plant and equipment account, reconfirming completion of the facilities and their recognition as assets. However, obtaining approval and commencing full-scale operations remain priorities to be addressed. - FY2019-Q3AdvancedAnnual report
「The new facilities constructed and completed on the premises of the Tokiwa Plant to substantially increase production capacity for pharmaceutical active ingredients and intermediates are as follows.」
For the pharmaceutical facilities at the Tokiwa Plant, the amount already paid reached approximately ¥3.6 billion against total investment of approximately ¥3.6 billion, indicating that investment payments had been completed. The facilities had already been completed in May 2018, and increased pharmaceutical production capacity was stated. - FY2019-Q2RestatedAnnual report
「The new facilities constructed and completed on the premises of the Tokiwa Plant to substantially increase production capacity for pharmaceutical active ingredients and intermediates are as follows.」
It was reconfirmed that the pharmaceutical facilities at the Tokiwa Plant had been completed, with total investment of approximately ¥3.6 billion, approximately ¥3.3 billion already paid, construction commencing in April 2017, completion in May 2018, and increased pharmaceutical production capacity stated. Completion had already been reported by the previous quarter, and there is no new completion milestone. - FY2019-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 16 September 2016, the Company decided to construct new facilities on the premises of the Tokiwa Plant in Iwaki, Fukushima Prefecture, to substantially increase its production capacity for pharmaceutical active ingredients and intermediates. Construction of the facilities had been under way since April 2017, and the Company hereby announces that construction has now been completed, as described below.」
The pharmaceutical facilities at the Tokiwa Plant were completed in May 2018. Total investment was approximately ¥3.6 billion, of which approximately ¥2.7 billion had been paid, and the facilities are expected to increase pharmaceutical production capacity. However, obtaining regulatory approval, commencing full-scale operations and securing new projects remain future challenges. - FY2018AdvancedAnnual report
「New pharmaceutical API and intermediate production facilities at the Tokiwa Plant」
Progress on the new pharmaceutical facilities at the Tokiwa Plant was reported as follows: total investment of approximately ¥3.4 billion, approximately ¥2.4 billion already paid, completion in May 2018, and increased pharmaceutical production capacity. Although construction of the facilities has been completed, obtaining regulatory approval, commencing full-scale operations and securing new projects remain future challenges. - FY2018-Q3AdvancedAnnual report
「Fixed assets at the end of the third quarter increased by ¥1,935 million from the end of the previous fiscal year to ¥12,560 million. This was mainly due to an increase in construction in progress.」
Fixed assets increased by ¥1,935 million from the end of the previous fiscal year due to an increase in construction in progress. This indicates further progress in construction and investment related to the pharmaceutical equipment plan at the Tokiwa Plant, but does not indicate that construction has been completed or that full-scale operations have begun. - FY2018-Q2AdvancedAnnual report
「At the end of the second quarter, fixed assets had increased by ¥1,082 million from the end of the previous fiscal year to ¥11,707 million, mainly due to an increase in construction in progress.」
Fixed assets increased by ¥1,082 million from the end of the previous fiscal year due to an increase in construction in progress. The figures provide additional evidence of construction and investment progress related to the pharmaceutical facilities plan at the Joban Plant, but no completed construction or full-scale operational results are indicated. - FY2018-Q1AdvancedAnnual report
「At the end of the first quarter, fixed assets had increased by ¥690 million from the end of the previous fiscal year to ¥11,315 million, mainly due to an increase in construction in progress.」
Construction in progress related to the pharmaceutical facilities plan at the Joban Plant increased, driving a ¥690 million increase in fixed assets from the end of the previous fiscal year. No completed construction or full-scale operational results were indicated. - FY2017AdvancedAnnual report
「Major completed additions, expansions and renovations of facilities during the fiscal year included ¥156 million for new pollution-control facilities at the Joban Plant and ¥146 million for expansion of pharmaceutical manufacturing facilities.」
The ¥146 million expansion of pharmaceutical manufacturing facilities was reported as completed. The pharmaceutical facilities plan was also described as involving total investment of approximately ¥3.4 billion, approximately ¥1.1 billion already paid, construction starting in April 2017 and completion scheduled for March 2018, indicating progress on the plan. - FY2017-Q3RestatedAnnual report
「At a Board of Directors meeting held on 16 September 2016, we decided to construct new facilities on the premises of the Joban Plant (Iwaki, Fukushima) to substantially increase production capacity for pharmaceutical APIs and intermediates. Completion was scheduled for March 2018, but full-scale operation was expected to begin in the second half of fiscal 2018 after review and approval by the relevant authorities and major business partners.」
The plan for API and intermediate facilities at the Joban Plant is reiterated, with an investment of approximately ¥3.4 billion, completion scheduled for March 2018 and full-scale operation scheduled for the second half of fiscal 2018. No new completion or operational results are indicated. - FY2017-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 16 September 2016, we decided to construct new facilities on the premises of the Tokiwa Plant in Iwaki, Fukushima Prefecture, to substantially expand production capacity for pharmaceutical active ingredients and intermediates. Completion was scheduled for March 2018, with full-scale operations expected to begin in the second half of fiscal 2018 after the required reviews and permits from the relevant authorities and major customers. Investment: approximately ¥3.4 billion; construction start: April 2017; scheduled completion: March 2018.」
The Board approved construction of pharmaceutical active ingredient and intermediate facilities at the Tokiwa Plant, with investment of approximately ¥3.4 billion, construction beginning in April 2017, completion scheduled for March 2018 and full-scale operations expected in the second half of fiscal 2018. - FY2016First statedAnnual report
「Jōban Plant (Iwaki, Fukushima) | Pharmaceutical facilities | Undetermined | — | Internal funds and borrowings | August 2016 | December 2017 | Increased pharmaceutical production capacity」
Provides the planned start and completion dates, funding sources and expected increase in production capacity for the new pharmaceutical facilities.